ACP Updates Outpatient COVID-19 Treatment Guidance

Updated guidance from the American College of Physicians (ACP) clarifies best practices for managing confirmed COVID-19 cases in outpatient settings, with a continued focus on antiviral medications for high-risk individuals. The recommendations, published in Annals of Internal Medicine, emphasize the importance of timely treatment – within five days of symptom onset – for both nirmatrelvir/ritonavir and molnupiravir. ACP’s chief science officer, Dr. Amir Qaseem, detailed the updates, which represent the final iteration of a living guideline that began in 2022.

Antiviral Timing and Risk Stratification

The guidance highlights that nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio) demonstrate benefit only when initiated promptly after symptoms begin. Evidence indicates that nirmatrelvir/ritonavir reduces the risk of all-cause mortality, hospitalizations, and shortens recovery time, with improved outcomes observed at 20 days post-treatment. Molnupiravir, whereas showing a more modest effect, can improve recovery up to 28 days and reduce the duration of symptoms. Healio reports that these findings underpin the recommendation for their use within the five-day window.

A crucial element of effective outpatient COVID-19 management, according to the ACP, is careful risk stratification. Increasing age remains the strongest predictor of progression to severe disease. Individuals with underlying chronic conditions – including asthma, cancer, cardiovascular disease, chronic kidney or liver disease, diabetes, obesity, or a history of smoking – are also at heightened risk. Pharmacologic treatment should be considered for these high-risk patients within five days of symptom onset.

Guidance Evolution and Evidence Base

The ACP’s recommendations are based on a “living, rapid review” of available evidence, regularly updated since 2022 to incorporate new research. This approach reflects the dynamic nature of the pandemic and the evolving understanding of COVID-19. However, Dr. Qaseem explained that the guideline has now been retired from “living status” as recent surveillance and updates have not yielded significant changes to the core conclusions. The ACP anticipates that further high-quality, randomized controlled trials evaluating current treatments are unlikely.

The updated guidance also reaffirms previous recommendations against the use of ivermectin and sotrovimab for managing COVID-19 in outpatient settings. These recommendations are rooted in a rigorous evaluation of the evidence, demonstrating a lack of benefit for these treatments.

GRADE Methodology and Adoption

The ACP’s clinical guidance is highly regarded within the medical community, largely due to its scientific rigor and evidence-based approach. The ACP is the only medical specialty in the U.S. – and internationally – recognized as a Grading of Recommendations Assessment, Development and Evaluation (GRADE) Center. This designation signifies adherence to a transparent and structured framework for developing healthcare guidance, involving systematic evidence identification, evaluation, and dissemination.

Dr. Qaseem emphasized that the ACP’s clinical considerations provide detailed information on initiating treatment, risk stratification, and potential warnings and precautions associated with antiviral therapies.

What to Consider When Prescribing

The decision to prescribe antiviral treatment for COVID-19 in the outpatient setting requires careful consideration of individual patient risk factors. Beyond age and chronic conditions, clinicians should assess for current or former smoking status. It’s important to remember that these medications are most effective when started early in the course of illness, ideally within five days of symptom onset.

The ACP guidance also underscores the importance of clear communication with patients regarding potential drug interactions and adverse effects. Nirmatrelvir/ritonavir, for example, has numerous drug interactions that must be carefully evaluated before prescribing.

Public Health Surveillance and Future Updates

While the ACP has retired this specific guideline from “living status,” ongoing surveillance of COVID-19 trends and the emergence of new variants remains critical. Public health agencies, such as the Centers for Disease Control and Prevention (CDC), continue to monitor the virus and update recommendations as needed. The CDC provides resources for healthcare professionals and the public on COVID-19 prevention, testing, and treatment.

Future updates to the ACP’s guidance may be warranted if significant new evidence emerges, such as the development of novel antiviral therapies or substantial changes in the epidemiology of COVID-19. However, the current recommendations provide a solid foundation for managing COVID-19 in the outpatient setting based on the best available evidence.

For more information: Amir Qaseem, MD, PhD, MHA, MGIN, MRCP, FACP, can be reached at [email protected] or on X at @pennstate2003.